SEC EDGARSep 21$CHE

MCNAMARA KEVIN J sold $1.0M of CHE

MCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $501.40 ($1.00M total) on 2026-09-18.

Original reporting

SEC EDGAR · MCNAMARA KEVIN J

Published Sep 21, 2026, 4:24 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 21, 2026, 4:47 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CHE

Neutral

medium confidence

Mentioned

$CHE

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CHENeutralLow

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it adds to the flow of insider activity data.

Market read

Routine insider sale with limited immediate trading impact.

What to watch

No disclosed reason for the sale; monitor upcoming earnings for broader context.

Relevance 6/10Novelty 4/10Timing: post filing

Background

Form 4 filings disclose insider transactions; investors watch for material changes in insider holdings.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CHENeutralMedium confidence

Context

CEO Kevin J. McNamara sold 2,000 shares for $1.0M, reducing his stake to 68,418 shares.

Expected impact

Potential slight downward pressure in the short term.

Evidence & confidence

Sale size is under $1M and represents a small percentage of total holdings; market reaction likely limited.

Market effects

Sector

Minimal impact on the pharmaceutical sector.

Regional

Limited to US markets where CHE is listed.

Global

Low

Counterpoint

What could challenge this read

The sale could be unrelated to confidence and merely a personal liquidity event.

Key entities

Company
Chemed Corp
US-listed healthcare services provider (ticker CHE).
Individual
Kevin J. McNamara
President and CEO of Chemed Corp.

Read at source ← All news

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

tradingview.comOct 29

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

finance.yahoo.comOct 29

$CHEHigh

Chemed Corp (CHE) Q3 2026 Earnings Call Highlights: VITAS Strength Drives 28% EPS Growth

Chemed Corp (CHE) reported Q3 2026 earnings with VITAS driving 28% EPS growth. Roto-Rooter saw a 2.5% EBITDA decline due to higher marketing and fuel costs. VITAS faces regulatory audits, reviewing $12-$14M in revenue. Chemed anticipates continued cost headwinds in Q4. Management discussed hiring, acquisitions, and lead generation strategies.

finance.yahoo.comOct 28

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

seekingalpha.comOct 28

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.